JPH09175948A - Hair tonic cosmetic - Google Patents
Hair tonic cosmeticInfo
- Publication number
- JPH09175948A JPH09175948A JP35390995A JP35390995A JPH09175948A JP H09175948 A JPH09175948 A JP H09175948A JP 35390995 A JP35390995 A JP 35390995A JP 35390995 A JP35390995 A JP 35390995A JP H09175948 A JPH09175948 A JP H09175948A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- eugenol
- glycoside
- cosmetic
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 49
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 230000001256 tonic effect Effects 0.000 title abstract 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Natural products COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 27
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000005770 Eugenol Substances 0.000 claims abstract description 21
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960002217 eugenol Drugs 0.000 claims abstract description 21
- -1 eugenol glycoside Chemical class 0.000 claims abstract description 17
- 229930182470 glycoside Natural products 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- 229940095064 tartrate Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 36
- 230000003779 hair growth Effects 0.000 abstract description 24
- 230000001737 promoting effect Effects 0.000 abstract description 12
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 10
- 210000004761 scalp Anatomy 0.000 abstract description 9
- 208000001840 Dandruff Diseases 0.000 abstract description 8
- 201000004384 Alopecia Diseases 0.000 abstract description 7
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000003405 preventing effect Effects 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 2
- 239000006260 foam Substances 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 239000003595 mist Substances 0.000 abstract description 2
- 230000002093 peripheral effect Effects 0.000 abstract description 2
- 239000002453 shampoo Substances 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract description 2
- 239000012730 sustained-release form Substances 0.000 abstract description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 3
- 235000002906 tartaric acid Nutrition 0.000 abstract 3
- 239000011975 tartaric acid Substances 0.000 abstract 3
- 231100000360 alopecia Toxicity 0.000 abstract 2
- 229930182473 O-glycoside Natural products 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 7
- 230000003658 preventing hair loss Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- NPORIZAYKBQYLF-LREBCSMRSA-N nicotinyl alcohol tartrate Chemical compound OCC1=CC=CN=C1.OC(=O)[C@H](O)[C@@H](O)C(O)=O NPORIZAYKBQYLF-LREBCSMRSA-N 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003662 hair growth rate Effects 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- LPRNQMUKVDHCFX-RKQHYHRCSA-N Glucovanillin Chemical compound COC1=CC(C=O)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 LPRNQMUKVDHCFX-RKQHYHRCSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LPRNQMUKVDHCFX-UHFFFAOYSA-N Vanilloside Natural products COC1=CC(C=O)=CC=C1OC1C(O)C(O)C(O)C(CO)O1 LPRNQMUKVDHCFX-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- LPRNQMUKVDHCFX-RGDJUOJXSA-N glucovanillin Natural products COC1=CC(C=O)=CC=C1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 LPRNQMUKVDHCFX-RGDJUOJXSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000008496 α-D-glucosides Chemical class 0.000 description 1
- 150000008498 β-D-glucosides Chemical class 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、酒石酸ニコチニッ
クアルコール及びオイゲノール配糖体を含有してなる養
毛化粧料に関して、詳しくは、酒石酸ニコチニックアル
コールの血行促進作用及びオイゲノール配糖体から頭皮
常在菌により遊離されるオイゲノールによる5αレダク
ターゼの活性阻害能を有し、育毛効果、脱毛予防効果及
びふけ防止効果に優れた養毛化粧料に関する。TECHNICAL FIELD The present invention relates to a hair nourishing composition comprising nicotinic alcohol tartrate and eugenol glycoside, and more specifically, to blood circulation promoting action of nicotinic alcohol tartrate and eugenol glycoside to normal scalp. The present invention relates to a hair nourishing cosmetic composition which has the ability to inhibit the activity of 5α reductase by eugenol released by bacteria and is excellent in the hair growth effect, hair loss prevention effect and dandruff prevention effect.
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】従来よ
り、トウガラシチンキ、センブリエキス、朝鮮ニンジン
エキス、ニコチン酸、ニコチン酸メチル等の頭皮の血行
促進物質等を配合してなる養毛化粧料は知られている。
しかしながら、育毛、脱毛防止、ふけ防止等の効果を充
分に発現する程に有効なる物質の発現にまでは至ってい
ない。更に、近年、育毛に関し、ホルモンの関与が示唆
されている。つまり、毛母細胞を含めた毛包に於いて、
男性ホルモン(テストステロン)は、5α- レダクター
ゼ(Δ4 −3−ケトステロイド5α- オキシドリダクタ
ーゼ)により、活性型男性ホルモン(ジヒドロテストス
テロン)に活性化され、更に受容体と結合し、核に取り
込まれ、DNAレベルで情報を伝達する。伝達された情
報により、ケラチン合成に関与する酵素合成が制御さ
れ、毛髪のケラチン合成を抑制し、毛髪の成長が低下
し、最終的に脱毛を促進させる。従って、養毛剤開発に
あたり、頭毛及び頭皮に於いて男性ホルモンの活性化酵
素である5α- レダクターゼの活性阻害物質に関する研
究が注目されている。BACKGROUND OF THE INVENTION Conventionally, a hair nourishing cosmetic composition containing a scalp blood circulation-promoting substance such as capsicum tincture, assembly extract, ginseng extract, nicotinic acid, methyl nicotinate, etc. has hitherto been known. Are known.
However, a substance that is effective enough to exert effects such as hair growth, hair loss prevention and dandruff prevention has not yet been developed. Furthermore, in recent years, it has been suggested that hormones are involved in hair growth. In other words, in the hair follicle containing hair matrix cells,
Male hormone (testosterone), due 5α- reductase (delta 4-3-keto steroid 5α- oxidoreductase), is activated to active androgen (dihydrotestosterone), and further coupled to the receptor, it is incorporated into the nucleus, Transmits information at the DNA level. The transmitted information controls enzyme synthesis involved in keratin synthesis, suppresses keratin synthesis in hair, reduces hair growth, and finally promotes hair loss. Therefore, in the development of a hair restorer, attention has been paid to research on an activity inhibitor of 5α-reductase, which is an androgen activating enzyme in hair and scalp.
【0003】しかしながら、男性型脱毛症は男性ホルモ
ンの過剰作用が原因の一つと言われているが、血行の不
良や毛母細胞の活性低下、皮脂腺の肥大化、頭皮の線維
化等の現象が複雑に絡みあって生じていると推察されて
いる。However, androgenetic alopecia is said to be one of the causes of excess action of androgen, but it is caused by phenomena such as poor circulation, decreased activity of hair matrix cells, hypertrophy of sebaceous glands, and fibrosis of scalp. It is presumed that they are complicatedly intertwined.
【0004】男性ホルモンの過剰作用が原因といわれる
毛母細胞の活性低下や皮脂腺の肥大化を抑制するため
に、単に男性ホルモン剤等を養毛剤として用いても、育
毛作用を発現するまでには至らないのが現状である。ま
た、毛母細胞賦活剤や血行促進剤を単独で用いても、良
好な成績は得られない。[0004] In order to suppress the decrease in the activity of hair mother cells and the enlargement of the sebaceous glands, which are said to be caused by the excessive action of male sex hormones, even when male sex hormone preparations and the like are simply used as hair nourishing agents, the hair growth effect is not exhibited. The current situation is that there are none. In addition, good results cannot be obtained even when the hair matrix activator or the blood circulation promoter is used alone.
【0005】更に、従来より使用されている血行促進物
質は、皮膚刺激が強くその配合量に制限があったり、血
行促進の持続時間が短いという欠点がある。また、毛髪
の栄養成分も低濃度では皮膚への浸透性が低く、かつ単
独では効果が十分に発揮されないという問題点があっ
た。Further, conventionally used blood circulation promoting substances have drawbacks that they are strongly irritated to the skin and the amount thereof is limited, and the duration of blood circulation promotion is short. Further, there is a problem in that the nutritional component of hair has a low permeability to the skin at a low concentration, and the effect alone is not sufficiently exerted.
【0006】前記の問題点を解決する手段として、特開
平5−58850号公報、特開平5−1399336号
公報、特開平5−170625号公報等を始めとして数
多くの養毛・育毛剤が提案されているが、末梢血流を促
進し、毛母細胞の賦活化をする物質を単独で用いても格
段の育毛作用については見出せなかった。As means for solving the above-mentioned problems, a large number of hair-growth and hair-growing agents have been proposed, including Japanese Patent Application Laid-Open Nos. 5-58850, 5-139336 and 5-170625. However, no remarkable hair-growth effect was found even when a substance that promotes peripheral blood flow and activates hair matrix cells was used alone.
【0007】本発明者らは、このような実情に鑑み、頭
皮の末梢血流の促進および毛母細胞の賦活作用のある物
質について、鋭意研究を重ねた結果、酒石酸ニコチニッ
クアルコールを、また、5α- レダクターゼの活性阻害
能を有するオイゲノールが必要に応じて頭皮常在菌で遊
離されるオイゲノール配糖体の双方を含有した養毛化粧
料が、各成分の相乗効果により、本発明の目的である優
れた養毛、育毛効果を発現することを見いだし、本発明
を完成した。In view of such circumstances, the inventors of the present invention have conducted extensive studies on a substance having an action of promoting peripheral blood flow in the scalp and activating hair matrix cells. As a result, nicotinic tartrate, and For the purpose of the present invention, a hair nourishing cosmetic composition containing both eugenol glycosides, which are released from the scalp indigestible eugenol having the ability to inhibit the activity of 5α-reductase, is obtained by the synergistic effect of each component. The present invention has been completed by discovering that a certain excellent hair nourishing and hair-growing effect is exhibited.
【0008】[0008]
【課題を解決するための手段】すなわち、酒石酸ニコチ
ニックアルコール及びオイゲノール配糖体を含有する養
毛化粧料によって本発明の目的が達成される。That is, the object of the present invention is achieved by a hair nourishing cosmetic containing nicotinic alcohol tartrate and eugenol glycoside.
【0009】[0009]
【発明の実施の形態】以下、本発明の構成について詳述
する。本発明に用いる酒石酸ニコチニックアルコール
は、公知の物質であり、末梢血流促進作用を有する薬剤
として、メニエル病及びメニエル病症候群の治療薬、ま
たは各種末梢循環障害の治療薬として使用されている。
本化合物の化学的性質は下記の通りである。 化学名:3−ピリジンメタノール d−タートレイト 分子式:C6 H7 NO・C4 H6 O6 分子量:259.22 融点:145〜150℃(分解) 上記の酒石酸ニコチニックアルコールは公知の物質であ
り容易に入手が可能であるが、以下の方法により容易に
調製が可能である。すなわち、ニコチニックアルコール
を1〜30重量%に、またd−酒石酸を1〜10重量%
にそれぞれエチルアルコールに溶解させる。次に、等モ
ルになるように両液を室温で混合し、1時間程度放置す
る。その後に、生成した結晶を瀘過し、目的の酒石酸ニ
コチニックアルコールを得ることができる。DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The configuration of the present invention will be described below in detail. The nicotinic alcohol tartrate used in the present invention is a known substance, and is used as a drug having a peripheral blood flow promoting action, as a therapeutic drug for Meniere's disease and Meniere's disease syndrome, or as a therapeutic drug for various peripheral circulatory disorders.
The chemical properties of this compound are as follows. Chemical name: 3-pyridinemethanol d- Tatoreito molecular formula: C 6 H 7 NO · C 4 H 6 O 6 Molecular weight: 259.22 mp: 145-150 ° C. (decomposition) above tartaric nicotinyl nick alcohol is a known substance Although it is easily available, it can be easily prepared by the following method. That is, 1 to 30% by weight of nicotinic alcohol and 1 to 10% by weight of d-tartaric acid.
Dissolve in ethyl alcohol. Next, both solutions are mixed at room temperature so as to be equimolar and left for about 1 hour. After that, the generated crystals can be filtered to obtain the desired nicotinic tartrate alcohol.
【0010】本発明に用いられる酒石酸ニコチニックア
ルコールの含有量は、共に本発明の目的である、育毛効
果、脱毛予防効果を示す範囲を検討した結果、養毛化粧
料の総量を基準として、0.001〜15.0重量%
(以下、wt%と略する)であればよく、より好ましく
は0.01〜5.0wt%である。The content of the nicotinic tartrate alcohol used in the present invention was 0 based on the total amount of the hair nourishing cosmetics as a result of examining the ranges showing the hair-growth effect and the hair loss prevention effect, which are the objects of the present invention. 0.001-15.0% by weight
(Hereinafter, abbreviated as “wt%”), and more preferably 0.01 to 5.0 wt%.
【0011】本発明で言うオイゲノール配糖体とは、グ
ルコース、ガラクトース、マンノース、ラムノース、キ
シロース、グルコサミン、ガラクトサミン等の単糖類、
ラクトース、マルトース、シュークロース等の二糖類等
の糖類とオイゲノールとがO−グリコシド結合された化
合物である。これらオイゲノール配糖体は、公知の方法
で容易に合成することができる。例えば、U.S.P.
第3201385号に記載のアルブチンの合成方法に準
じてα−体とβ−体の混合体としてのオイゲノール配糖
体が得られる。また、フレバー・アンド・フレグランス
・ジャーナル(14巻、163−167頁、1989
年)に記載のグルコバニリンの合成方法に準じるとβ−
体だけの合成が出来る。これらオイゲノール配糖体の中
でも、その効果の発現の程度から、好ましくはグルコー
ス配糖体であり、具体的には、オイゲニルα−D−グル
コシド及び/又はオイゲニルβ−D−グルコシドであ
る。この場合、β−体が好ましいが、α−体が含まれて
いても効果に特に問題は無い。そして、これらオイゲノ
ール配糖体は、頭皮常在菌により、オイゲノールと糖部
分に適宜分解され、徐放性の育毛効果、脱毛予防効果及
びふけ防止効果を示す。The eugenol glycoside referred to in the present invention is a monosaccharide such as glucose, galactose, mannose, rhamnose, xylose, glucosamine or galactosamine,
It is a compound in which saccharides such as disaccharides such as lactose, maltose, and sucrose and eugenol are O-glycoside-bonded. These eugenol glycosides can be easily synthesized by a known method. For example, U.S. S. P.
According to the method for synthesizing arbutin described in No. 3201385, eugenol glycoside as a mixture of α-form and β-form can be obtained. Also, the Flavor and Fragrance Journal (14, 163-167, 1989).
Years) β-based on the method of synthesizing glucovanillin
You can synthesize only the body. Among these eugenol glycosides, glucose glycosides are preferable in terms of the degree of their effects, and specifically, eugenyl α-D-glucoside and / or eugenyl β-D-glucoside. In this case, the β-form is preferred, but the effect is not particularly problematic even if the α-form is contained. Then, these eugenol glycosides are appropriately decomposed into eugenol and sugar moieties by the scalp resident bacteria, and exhibit a sustained release hair growth effect, hair loss prevention effect, and dandruff prevention effect.
【0012】本発明に用いられるオイゲノール配糖体の
含有量は、共に本発明の目的である、育毛効果、脱毛予
防効果及びふけ防止効果を示す範囲を検討した結果、養
毛化粧料の総量を基準として、0.001〜15.0重
量%(以下、wt%と略する)であればよく、より好ま
しくは0.01〜5.0wt%である。The content of the eugenol glycoside used in the present invention was determined by studying the ranges showing the hair growth effect, hair loss prevention effect and dandruff prevention effect, which are the objects of the present invention. As a reference, it may be 0.001 to 15.0% by weight (hereinafter abbreviated as wt%), and more preferably 0.01 to 5.0% by weight.
【0013】本発明の養毛化粧料は、常法に従って、た
とえばヘアートニック、ヘアーローション、ヘアークリ
ーム、ヘアーコンディショナー、シャンプー、リンス、
ヘアージェル、ヘアーミスト、ヘアーフォーム等の剤型
に製造し、使用することが可能である。The hair nourishing cosmetic composition of the present invention can be prepared according to a conventional method, for example, a hairnic, a hair lotion, a hair cream, a hair conditioner, a shampoo, a conditioner.
It can be manufactured and used in dosage forms such as hair gel, hair mist, and hair foam.
【0014】本発明の養毛化粧料は、養毛、育毛および
/または脱毛予防のために、それを目的とする局所(頭
皮)に、その剤型に従って塗布または噴霧して適用され
る。The hair nourishing cosmetic composition of the present invention is applied or sprayed to a desired topical region (scalp) according to its dosage form for the purpose of preventing hair nourishment, hair growth and / or hair loss.
【0015】なお、本発明の養毛化粧料には、色素、香
料、殺菌剤、防腐剤、角質溶解剤、抗酸化剤等を本発明
の目的を達成する範囲で適宜配合することができる。The hair nourishing cosmetic composition of the present invention may appropriately contain a dye, a fragrance, a bactericide, an antiseptic agent, a keratolytic agent, an antioxidant and the like within a range to achieve the object of the present invention.
【0016】[0016]
【実施例】以下、実施例および比較例により本発明を詳
細に説明するが、本発明はこれらに限定されるものでは
ない。なお、本発明に使用した試験方法は下記の通りで
ある。The present invention will be described in detail below with reference to examples and comparative examples, but the present invention is not limited to these examples. The test method used in the present invention is as follows.
【0017】(1)マウス毛成長促進効果試験法 C3H系マウス(雄・8週齢・平均体重35g)の背部
中央の皮膚を電気バリカンで刈った後、シェーバーによ
り完全に除毛した。翌日より実施例および比較例の各試
料を被験部皮膚に毎日1回、一匹当り0.2ml塗布し
た。一試料に対して動物は一群10匹を使用した。な
お、対照群として基剤単独を塗布した。実験開始後14
日目に動物を屠殺し、被験部皮膚の写真撮影を行なっ
た。つぎに、写真を画像解析装置に取り込み、最初に毛
刈りした面積(A)と、発毛面積(B)を求め、さらに 発毛率(%)=〔(B)/(A)〕×100 を個々の動物について算出した。最後に、実施例または
比較例の各群の平均値を対照群の平均値により除した値
を毛成長促進効果として判定に用いた。(1) Test method for mouse hair growth promoting effect C3H mice (male, 8 weeks old, average body weight: 35 g) were shaved at the center of the back with electric clippers and then completely shaved by a shaver. From the next day, each sample of Example and Comparative Example was applied to the skin of the test part once a day, 0.2 ml per animal. A group of 10 animals was used for one sample. The base alone was applied as a control. 14 after the start of the experiment
On the day, the animals were sacrificed and the skin of the test area was photographed. Next, the photograph was taken into an image analyzer, and the area (A) of initial shaving and the area of hair growth (B) were determined. Further, the hair growth rate (%) = [(B) / (A)] × 100 Was calculated for each animal. Finally, the value obtained by dividing the average value of each group of the examples or comparative examples by the average value of the control group was used as a hair growth promoting effect in the determination.
【0018】(2)ヒト頭髪毛成長促進効果試験法 30〜40代の毛成長に衰えの認められる男性被験者1
0名の頭頂部の頭髪を直径約7mmの円形状に剃毛し
た。更に、毛刈り1日後及び3日後に林らの方法(ブリ
ティッシュ・ジャーナル・オブ・デルマトロジー、12
5巻、123頁、1991年)により毛成長速度(成長
の毛長/日)を対象部位の毛髪(約30〜40本)につ
いて求めて、その平均値を計算した(A)。次に各被験
者に被験部位を中心として、実施例又は比較例の試料を
毎日朝夕2回、約3ml塗布し、よくマッサージさせ
た。試験開始3ケ月目に同様にして同一部位の毛成長速
度の測定を行い、平均値(B) を計算した。効果の判定
は、各養毛化粧料使用前後の比(B)/(A)を比較す
ることにより行った。(2) Test method for human hair growth promoting effect Male subject 1 in the thirties and forties with a decline in hair growth
The hair at the top of the head was shaved into a circular shape having a diameter of about 7 mm. One and three days after shaving, the method of Hayashi et al. (British Journal of Dermatology, 12
Volume 5, p. 123, 1991), the hair growth rate (growth length / day) was determined for the hair (about 30 to 40 hairs) at the target site, and the average value was calculated (A). Then, about 3 ml of the sample of the Example or Comparative Example was applied to each test subject twice daily in the morning and evening, and massaged well. The hair growth rate at the same site was measured in the same manner 3 months after the start of the test, and the average value (B) was calculated. The effect was determined by comparing the ratio (B) / (A) before and after use of each hair nourishing cosmetic.
【0019】(3)実用試験法 男性型脱毛症患者20名の頭部に毎日朝夕2回、連続6
ケ月間試料を塗布した後の効果を評価した。試験結果
は、育毛効果、脱毛予防効果及びふけ防止効果の各項に
対して、「生毛が剛毛化した或は剛毛が増加した」、
「脱毛が少なくなった」と回答した人数で示した。(3) Practical test method 20 heads of male pattern baldness were applied to the heads twice daily in the morning and evening, and continuously 6 times.
The effect after applying the sample for a month was evaluated. The test result shows that “hairy hair has become bristle or bristles have increased” for each item of hair growth effect, hair loss prevention effect and dandruff prevention effect.
The number of respondents who said "hair loss has decreased" is shown.
【0020】実施例1〜13、比較例1〜4(ヘアート
ニック) 表1の原料組成において、表2に記載の如く有効成分を
配合してヘアートニックを調製し、前記の諸試験を実施
した。尚、オイゲノール配糖体は、α−体とβ−体の混
合物(3:7)、またはβ−体を使用した。Examples 1 to 13 and Comparative Examples 1 to 4 (Heartonic) In the raw material composition shown in Table 1, the active ingredients were blended as shown in Table 2 to prepare a hairnic, and the above-mentioned tests were carried out. . As the eugenol glycoside, a mixture of α-form and β-form (3: 7) or β-form was used.
【0021】[0021]
【表1】 [Table 1]
【0022】[0022]
【表2】 [Table 2]
【0023】(1)調製法 表1に記載の(B)成分を(A)成分中に溶解させた
後、(C)成分を添加し、混合攪拌分散して容器に充填
した。使用時には内容物を均一に振盪分散して使用し
た。(1) Preparation Method After dissolving the component (B) shown in Table 1 in the component (A), the component (C) was added, and the mixture was stirred and dispersed to fill a container. At the time of use, the contents were uniformly shaken and used.
【0024】(2)特性 各ヘアートニックの諸試験を実施した結果を表2に示し
た。表2の通り、比較例1〜4はマウス毛成長促進効果
およびヒト頭髪毛成長促進効果が低く、実用試験の結果
も良好ではなかった。(2) Characteristics Table 2 shows the results of various tests conducted on each heartnic. As shown in Table 2, in Comparative Examples 1 to 4, the mouse hair growth promoting effect and the human hair growth promoting effect were low, and the results of the practical test were also not good.
【0025】一方、実施例1〜13の本発明の養毛化粧
料は、高いマウス毛成長促進効果およびヒト頭髪毛成長
促進効果を示し、さらに実用試験の結果も良好であり、
諸試験の全てにわたって明らかに良好な結果を示した。
なお、いずれの実施例の養毛化粧料を用いた場合にも、
マウスおよびヒトに炎症、その他副作用と考えられる症
状は発現せず、本発明の養毛化粧料は安全性にも優れる
ことが明らかであった。On the other hand, the hair nourishing cosmetics of the present invention of Examples 1 to 13 show a high mouse hair growth promoting effect and a human hair growth promoting effect, and the results of practical tests are also good.
Clearly good results were obtained over all of the tests.
In addition, when using the hair restoration cosmetics of any of the examples,
No inflammation or other symptoms considered to be side effects occurred in mice and humans, and it was clear that the hair restoration cosmetic of the present invention was also excellent in safety.
【0026】[0026]
【発明の効果】本発明の養毛化粧料は、毛母細胞の賦活
化作用を有し、育毛効果、脱毛予防効果、ふけ防止効果
および安全性に優れる。EFFECTS OF THE INVENTION The hair nourishing cosmetic composition of the present invention has an activity of activating hair mother cells, and is excellent in hair growth effect, hair loss prevention effect, dandruff prevention effect and safety.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 西尾 裕幸 神奈川県小田原市寿町5丁目3番28号 鐘 紡株式会社化粧品研究所内 (72)発明者 中川 典昭 神奈川県小田原市寿町5丁目3番28号 鐘 紡株式会社化粧品研究所内 ─────────────────────────────────────────────────── ─── Continuation of front page (72) Hiroyuki Nishio, 5-3 28, Kotobuki-cho, Odawara-shi, Kanagawa Cosmetics Research Institute, Kanebo Co., Ltd. (72) Noriaki Nakagawa 5--3, Shou-cho, Odawara-shi, Kanagawa No. 28 Kanebo Co., Ltd.Cosmetics Research Laboratory
Claims (1)
ノール配糖体とを含有することを特徴とする養毛化粧
料。1. A hair nourishing cosmetic comprising nicotinic tartrate alcohol and eugenol glycoside.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35390995A JPH09175948A (en) | 1995-12-25 | 1995-12-25 | Hair tonic cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35390995A JPH09175948A (en) | 1995-12-25 | 1995-12-25 | Hair tonic cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09175948A true JPH09175948A (en) | 1997-07-08 |
Family
ID=18434046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP35390995A Pending JPH09175948A (en) | 1995-12-25 | 1995-12-25 | Hair tonic cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH09175948A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990055304A (en) * | 1997-12-27 | 1999-07-15 | 성재갑 | 5α-reductase activity inhibiting composition containing cloves |
-
1995
- 1995-12-25 JP JP35390995A patent/JPH09175948A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990055304A (en) * | 1997-12-27 | 1999-07-15 | 성재갑 | 5α-reductase activity inhibiting composition containing cloves |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09295921A (en) | Hair growing and tonic agent | |
| EP0998907A1 (en) | Hair tonic composition comprising adenosine | |
| JPH05286835A (en) | Hair-raising cosmetic | |
| JP4162823B2 (en) | Hair cosmetics | |
| JPH0853327A (en) | Hair nourishing and hair-restoring agents using allantoin or its derivatives | |
| JP2002080327A (en) | Hair grower | |
| JPH09175948A (en) | Hair tonic cosmetic | |
| JP3162962B2 (en) | Hair restoration | |
| JP2546813B2 (en) | Hair nourishing cosmetics | |
| JP3133532B2 (en) | Hair restoration cosmetics | |
| JP2774071B2 (en) | Hair restoration cosmetics | |
| JP3435008B2 (en) | Hair restoration cosmetics | |
| JP3624318B2 (en) | Hair nourishing agent | |
| JP3113763B2 (en) | Hair growth and hair growth fees | |
| JP3034410B2 (en) | Ergosterol glycoside and hair growth / hair restoration containing the same | |
| JP3014215B2 (en) | Hair restoration cosmetics | |
| JPH1077216A (en) | Hair-restoring cosmetic material | |
| JP2000178140A (en) | Hair tonic preparation | |
| JP2804834B2 (en) | Hair restorer and hair restoration cosmetics containing it | |
| JP3193544B2 (en) | Hair restoration cosmetics | |
| JP2000016920A (en) | Hair tonic cosmetic | |
| JP2869168B2 (en) | Hair restorer and hair restoration cosmetics containing it | |
| JPH0460446B2 (en) | ||
| JP3034412B2 (en) | Stigmasterol glycoside and hair-growth / hair restorer containing the same | |
| JP2955055B2 (en) | Hair restoration cosmetics |